|Bid||125.43 x 1300|
|Ask||125.87 x 800|
|Day's Range||124.86 - 127.09|
|52 Week Range||105.36 - 142.60|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||31.22|
|Earnings Date||Jan 26, 2022|
|Forward Dividend & Yield||1.88 (1.49%)|
|Ex-Dividend Date||Jan 13, 2022|
|1y Target Est||145.18|
Subscribe to Yahoo Finance Plus to view Fair Value for ABTLearn more
Investment company Harrington Investments, INC (Current Portfolio) buys Pfizer Inc, AerCap Holdings NV, sells Chubb, Abbott Laboratories, JPMorgan Chase, Danaher Corp, Shopify Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Harrington Investments, INC.
When it comes to underrated healthcare stocks that smart investors love, Abbott Laboratories (NYSE: ABT) takes the cake. On the contrary, it's exactly Abbott's willingness to compete in these spaces that makes the company one of the sturdiest. Given that Abbott has a market cap of about $238 billion and trailing revenue of $42.3 billion, it shouldn't surprise anyone that the business sometimes struggles to grow as aggressively as a smaller competitor might.
With the latest surge in COVID infections due to the more contagious Omicron variant, Abbott (ABT) is expected to report sequentially stronger diagnostics results for the fourth quarter.